File downloaded on 2026-11-24
Source URL: https://medicines.health.europa.eu/veterinary/en/600000032701

Avishield IB GI-13, lyophilisate for oculonasal suspension/use in drinking water for chickens

Authorised

- Infectious bronchitis virus, type 793/B, strain V-173/11, Live

Product identification

Medicine name:
Avishield IB GI-13, lyophilisate for oculonasal suspension/use in drinking water for chickens

Active substance:
Infectious bronchitis virus, type 793/B, strain V-173/11, Live

Target species:
Chicken

Route of administration:
Oculonasal use
Oral use

Product details

Active substance and strength:
Infectious bronchitis virus, type 793/B, strain V-173/11, Live

2.70 log 10 50% embryo infective dose / 1.00 Dose

Pharmaceutical form:
Lyophilisate for oculonasal suspension/use in drinking water

Withdrawal period by route of administration:
Oculonasal use:

- **Chicken**
  - All relevant tissues. 0 day

Oral use:

- **Chicken**
  - All relevant tissues. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AD07

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Germany

Available in:
Germany

Package description:
Cardboard box with 10 colourless glass vials (type I), which are closed with bromobutyl rubber stoppers and sealed with aluminium caps, of 2500 doses of vaccine
Cardboard box with 10 colourless glass vials (type I), which are closed with bromobutyl rubber stoppers and sealed with aluminium caps, of 5000 doses of vaccine

Cardboard box with 10 colourless glass vials (type I), which are closed with bromobutyl rubber stoppers and sealed with aluminium caps, of 1000 doses of vaccin

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Izo S.r.l.

Marketing authorisation date:
27/03/2020

Manufacturing sites for batch release:
Genera d.d.

Responsible authority:
Paul-Ehrlich-Institut

Authorisation number:
PEI.V.11998.01.1

Date of authorisation status change:
27/03/2020

Reference member state:
Netherlands

Procedure number:
NL/V/0301/001

Concerned member states:
Austria Belgium Croatia Czechia Denmark Estonia France Germany Greece Hungary Ireland Italy Latvia Lithuania Poland Portugal Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents